SEC Form 4 · accession 0001019687-15-004483
Medytox Solutions, Inc. · MMMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Eric Diamantis
Director
Period of report
Oct 27, 2015
Accepted (ET)
Dec 11, 2015 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001374536
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 27, 2015 | P | 100,000 | $1.00 | A | 850,000 | D | |
| Common StockF1 | Nov 2, 2015 | D | 850,000 | — | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF2 | $5.00 | Nov 2, 2015 | D | 100,000 | A | Apr 19, 2013 | Apr 19, 2017 | Common Stock | 100,000 | 0 | D |
| Options to Purchase Common StockF2 | $5.00 | Nov 2, 2015 | D | 50,000 | A | Apr 19, 2014 | Apr 19, 2017 | Common Stock | 50,000 | 0 | D |
| Options to Purchase Common StockF3 | $2.50 | Nov 2, 2015 | D | 100,000 | A | Apr 19, 2013 | Apr 19, 2017 | Common Stock | 100,000 | 0 | D |
| Options to Purchase Common StockF4 | $2.50 | Nov 2, 2015 | D | 50,000 | A | Apr 19, 2014 | Apr 19, 2017 | Common Stock | 50,000 | 0 | D |
Explanation of responses
- F1Disposed of pursuant to merger agreement among Medytox Solutions, Inc. ("Medytox"), CollabRx Merger Sub, Inc. ("Merger Sub"), and Rennova Health, Inc. ("Rennova") (f/k/a/ CollabRx, Inc.) in exchange for 348,193 shares of Rennova common stock.
- F2Cancelled pursuant to merger agreement and related transactions between Medytox and Rennova.
- F3Disposed of pursuant to the merger agreement among Medytox, Merger Sub and Rennova. The options were assumed by Rennova in the merger and replaced with options to purchase 40,963 shares of Rennova common stock at an exercise price of $6.11 per share.
- F4Disposed of pursuant to the merger agreement among Medytox, Merger Sub and Rennova. The options were assumed by Rennova in the merger and replaced with options to purchase 20,481 shares of Rennova common stock at an exercise price of $6.11 per share.